66 
1 Advisory Committee extend beyond strict technological 
2 assessments. They involve the social impact of a 
3 vast technology and therefore should have members 
4 representing all aspects of* its decision-making 
5 functions. 
6 We also recommend that the institutional 
7 biohazard committees expand their membership to include 
q representatives of the state or equivalent local health 
g department, as well as a member of the laboratory workers 
10 engaged in the recombinant DNA research. We recommend 
11 that a biohazards officer be appointed at each institu- 
12 tion, not just for those engaged in P 3 and P 4 level work. 
13 No NIH grant should be awarded until a 
14 specific kind of medical monitoring and record keeping 
15 is prepared. The medical monitoring plan should 
16 include periodic check-ups, and maintain accurate 
17 records on incidence of illness among all recombinant 
18 research personnel, all incidence of accidents, spills, 
19 and recombinant organism releases, and the location and 
20 conditions of recombinant DNA organism containment. 
21 These records will be particularly important if it 
22 should become necessary to establish legal liability 
23 at a future date in case of an accident or sickness. 
24 A central clearinghouse should be established 
25 at the federal level to which copies of all medical 
[158] 
